C4 Therapeutics (NASDAQ:CCCC) Insider Leonard Reyno Sells 10,000 Shares

C4 Therapeutics, Inc. (NASDAQ:CCCC) insider Leonard Reyno sold 10,000 shares of the business’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $2.22, for a total value of $22,200.00. Following the sale, the insider owned 156,382 shares of the company’s stock, valued at approximately $347,168.04. This represents a 6.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

C4 Therapeutics Stock Up 0.7%

Shares of NASDAQ:CCCC opened at $2.24 on Friday. The stock has a market capitalization of $216.59 million, a PE ratio of -1.34 and a beta of 2.93. The firm’s 50 day moving average price is $2.32 and its 200-day moving average price is $2.36. C4 Therapeutics, Inc. has a twelve month low of $1.09 and a twelve month high of $4.03.

C4 Therapeutics (NASDAQ:CCCC) last announced its earnings results on Thursday, November 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.03. C4 Therapeutics had a negative net margin of 395.51% and a negative return on equity of 64.40%. The company had revenue of $11.23 million during the quarter, compared to analyst estimates of $6.28 million. Analysts expect that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Barclays lowered their target price on C4 Therapeutics from $10.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Cowen began coverage on C4 Therapeutics in a research note on Tuesday, December 2nd. They issued a “buy” rating on the stock. TD Cowen began coverage on C4 Therapeutics in a research report on Tuesday, December 2nd. They set a “buy” rating on the stock. Stephens reissued an “overweight” rating and issued a $6.00 target price on shares of C4 Therapeutics in a report on Monday, September 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.25.

Institutional Trading of C4 Therapeutics

Several institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC lifted its holdings in C4 Therapeutics by 957.6% in the 1st quarter. AQR Capital Management LLC now owns 140,532 shares of the company’s stock worth $225,000 after purchasing an additional 127,244 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of C4 Therapeutics by 8.6% during the first quarter. Goldman Sachs Group Inc. now owns 622,720 shares of the company’s stock valued at $996,000 after buying an additional 49,065 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of C4 Therapeutics in the first quarter worth $43,000. Brookstone Capital Management purchased a new position in shares of C4 Therapeutics in the second quarter worth $42,000. Finally, R Squared Ltd bought a new position in shares of C4 Therapeutics during the second quarter worth $44,000. Hedge funds and other institutional investors own 78.81% of the company’s stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.